According to REGENXBIO's latest financial reports the company's current revenue (TTM) is $90.24 M. In 2022 the company made a revenue of $0.11 B a decrease over the years 2021 revenue that were of $0.47 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $90.24 M | -19.94% |
2022 | $0.11 B | -76.03% |
2021 | $0.47 B | 204.3% |
2020 | $0.15 B | 338.7% |
2019 | $35.23 M | -83.88% |
2018 | $0.21 B | 2002.42% |
2017 | $10.39 M | 126.48% |
2016 | $4.58 M | -39.58% |
2015 | $7.59 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |